Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug Discov Today. 2007 Feb;12(3-4):112-24. Epub 2006 Dec 15.

Targeting mammalian target of rapamycin (mTOR) for health and diseases.

Author information

  • 1Department of Pharmacology and Cancer Institute of New Jersey (CINJ) Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854 USA.

Erratum in

  • Drug Discov Today. 2008 Sep;13(17-18):824.

Abstract

The macrolide rapamycin is used clinically to treat graft rejection and restenosis. Mammalian target of rapamycin (mTOR) is a central controller of cellular and organism growth that integrates nutrient and hormonal signals, and regulates diverse cellular processes. New studies have linked mTOR to several human diseases including cancer, diabetes, obesity, cardiovascular diseases and neurological disorders. Recent data have also revealed that mTOR is involved in the regulation of lifespan and in age-related diseases. These findings demonstrate the importance of growth control in the pathology of major diseases and overall human health, and underscore the therapeutic potential of the mTOR pathway.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk